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increasing their rate of phagocytosis by antigen-pre-A Molecular Warhead and Its Target:
senting cells [6]. TG2 has a particular affinity for theTissue Transglutaminase glutamine-rich proteins of gluten (mainly the gliadins),
in which glutamine represents 30%–50% of the aminoand Celiac Sprue
acids. Most significantly, gluten-TG2 complexes can be
formed by a process of autocatalysis, and these com-
plexes appear to trigger autoantibody production by B
The substitution of a glutamine residue with 6-diazo- cells via so-called antibody crosspresentation. In addi-
5-oxo-norleucine (DON) transforms an immunodomi- tion, TG2 can deamidate some of the glutamine residues
nant gluten peptide into a potent inhibitor of tissue in gluten to glutamic acid, especially at low pH. The
transglutaminase. DON-modified peptides could be resulting de novo-introduced negative charge has been
useful for the study and therapy of celiac sprue. shown to increase the binding of gluten epitopes to
antigen-presenting HLA-DQ2 or -DQ8 proteins, enhanc-
Celiac Sprue is an inflammatory disease of the small ing their ability for antigenic presentation and potentiat-
intestine characterized by T cell infiltrates in the intesti- ing their T cell stimulatory capacity [4, 5, 7]. Various
nal epithelium and the underlying lamina propria (sup- immunodominant gluten peptides that are all substrates
porting connective tissue). This inflammation can lead of TG2 have been identified [8], and a unique 33-mer
to destruction of the microscopic small intestinal villi peptide within the 266-amino-acid-long 2 gliadin com-
and may drastically reduce the surface and destroy the ponent of gluten, which is resistant to intestinal prote-
structure of the resorptive intestinal epithelium [1]. The ases, was recently shown to harbour six partially over-
consequences of these actions are severe malabsorp- lapping HLA-DQ2 binding and T cell stimulatory peptide
tion of nutrients, vitamins, and minerals that can lead epitopes [9].
to profuse diarrhea, malnutrition, growth retardation, Since Celiac Sprue is among the most frequent geneti-
anemia, osteoporosis, or neurological dysfunction. cally determined disorders (prevalence around 1 in 200),
While this classical presentation of Celiac Sprue is rela- and since at present patients with Celiac Sprue have to
tively rare (ranging from 1:2,000 to 1:10,000 in the West- maintain a life-long strictly gluten-free diet which exacts
ern world), oligo- or even asymptomatic Celiac Sprue is a heavy toll on social interactions in our wheat-based
frequent, with an estimated prevalence of 1:200 in Eu- societies, pharmacological or immunological treatment
rope and the USA. Nonetheless, these oligo- or asymp- alternatives are urgently needed. The paper by Hausch
tomatic Celiac patients appear to run a high risk for later et al. [10] in this issue of Chemistry & Biology advances
disease exacerbation, secondary autoimmune disor- such endeavors one step further by constructing and
ders, or even malignancies, which are associated with testing gluten peptide-based inhibitors of TG2, which is
untreated Celiac Sprue [2, 3]. an obvious target since it is so intricately involved in
The disease has peculiar features, most of which were Celiac Sprue pathogenesis. The authors substituted the
uncovered only recently, that make it amenable to tar- glutamine in the immunodominant peptide substrate Ac-
geted intervention. The pathogenesis of Celiac Sprue is PQPQLPF-NH2 with a 6-diazo-5-oxo-norleucine (DON)
initiated by the ingestion of gluten, the storage protein residue to obtain a highly active and tight binding inhibi-
of wheat, barley and rye. Key traits of the disease in- tor of TG2 with low cellular toxicity. Ac-PQP(DON)LPF-
clude: (1) it usually remits upon strict dietary avoidance NH2 blocked more than 90% of TG2 activity at submicro-
of gluten, (2) it only manifests in patients with a unique molar concentrations and therefore could serve as a
genetic background for antigen presentation (specifi- lead compound for a novel class of TG2 inhibitors that
cally, the HLA-class II molecules DQ2 or DQ8), and (3) interrupt the vicious cycle of Celiac Sprue pathogenesis
it is tightly associated with circulating mucosal (IgA- (potentiation of gluten antigenicity via TG2, enhanced T
class) autoantibodies to the enzyme tissue transglutami- cell activation and inflammation, and finally increased
nase (TG2) [4, 5]. These features of the disease are production and release of TG2 as a response to the
closely linked with one another. Thus, when gluten pep- renewed inflammatory stimulus; see Figure). The overall
tides are presented via HLA-DQ2 or -DQ8 on antigen- approach is attractive and is complementary to strate-
presenting cells, such as macrophages, dendritic, or B gies envisaged by other groups to gain control of Celiac
cells, proliferation and proinflammatory cytokine pro- Sprue in the face of continuous gluten exposure as the
duction is generally elicited in intestinal T cells. result of a “normal” Western diet [11].
The autoantigenic enzyme TG2 is mainly expressed However, there is still some way to go before therapies
in the lamina propria (the major DQ2/DQ8-reactive T cell for pharmacological prevention of the disease and for
reservoir of the gut), and its expression is upregulated treatment become available. In this study, selectivity
by various stimuli, such as mechanical stress or bacte- of the inhibitory peptide was only checked against the
rial/viral infection, during active Celiac Sprue. The en- relatively unrelated -glutaminyl-transpeptidase, whereas
zyme catalyzes transamidation between a glutamine other closely related transglutaminases were not con-
residue of a glutamine-donor protein and a lysine resi- sidered, including factor XIII, a fundamental protein
due of a glutamine-acceptor protein, linking these pro- component of the blood clotting pathway, and TG1, TG3,
and TG5, which are essential for dermal epithelializationteins with a stable intermolecular isopeptide bond and
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Molecular Pathogenesis of Celiac Sprue and the Role of TG2 Inhibition
Infections or mechanical and chemical injury, which lead to an increased permeability of the mucosal epithelium, facilitate the entrance of
dietary gluten peptides into subepithelial regions. In the lamina propria, the gluten peptides encounter TG2 which is released from stressed
endothelia, fibroblasts, and inflammatory cells residing in the subepithelial region. Crosslinking of gluten by TG2 potentiates its uptake and
presentation by antigen-presenting cells, and its deamidation improves the binding to HLA-DQ2/8 molecules. The presentation of the gluten
peptides on professional antigen-presenting cells, in particular dendritic cells, triggers a vigorous T cell response that induces inflammation
and tissue remodeling (Th1 reaction) or antibody production (Th2 reaction). Inflammation stimulates further release of TG2, thus initiating a
vicious cycle that may be interrupted by TG2 inhibitors like Ac-PQP(DON)LPF-NH2.
A simplified scheme is shown, since both dendritic and T cells circulate to mesenterial lymph nodes (where encounters with T cells occur)
and back to the lamina propria.
[12]. Other studies have shown that while the knockout et al. [10] is a good example of translational research,
which uses the knowledge of the pathological mecha-of TG2 alone did not reveal a short-term phenotype [13],
abrogation of total TG activity is expected to cause nisms of a disease to generate targeted treatment strat-
egies.a severe pathology, since TG activity is required for
fundamental physiological processes like apoptosis,
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molecular diversity, but this perception will change as
a consequence of this innovative research producing
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Bridging the Synthetic
and Biopolymer Worlds libraries comprised of small molecule-peptide hybrids.
Though many methods for constructing peptide librar-with Peptide-Drug Conjugates
ies are available, the best physically connect each pep-
tide with its encoding DNA. Phage display is one exam-
ple of this methodology. Here, for each individual
Roberts and Li break the standard library mold by constituent of the library, the peptide is attached to the
generating hybrid libraries of small molecules tethered surface of a bacteriophage, a virus that infects bacteria,
to peptides. Hybrid libraries harness larger chemical and the DNA encoding the displayed peptide is encap-
and structural diversities and thus represent a new sulated by the phage particle (a convenient vehicle for
frontier in lead drug discovery. site-directed mutagenesis and sequencing to determine
the identity of the displayed peptide). Library diversity
At first glance, the report by Li and Roberts published is also vital for its value as a research tool. An underap-
in this issue of Chemistry & Biology would appear to be preciated source for generating diversity, whether DNA,
a move in the wrong direction [1]. Who would want to RNA, or peptide, is chemically synthesized degenerate
mess up a perfectly good small molecule by tethering oligonucleotides, made possible by phenomenally effi-
it to a peptide with the expected effective loss in phar- cient phosphoramidite coupling reactions. However,
macokinetics? The answer is affinity. The two research- when library diversities grow larger than about one mil-
ers have developed a clever way to boost drug affinities lion different peptides, assaying or screening each pep-
by tapping into the massive combinatorial potential of tide individually becomes impractical, and at this stage
peptide libraries. The technique holds promise for rap- strategies are required to select peptides with desirable
idly optimizing the binding affinities of lead molecules properties (e.g., binding to a particular receptor) before
without being confronted with the sometimes excruciat- amplifying the selectants. Another advantage of phage
ing task of preparing large libraries of small molecule display is that peptides selected for their desired proper-
analogs. ties can be readily amplified in an E. coli host. By re-
To accomplish their goal, Li and Roberts literally had peating the process of peptide selection and amplifica-
to bridge two important but distinct areas of drug lead tion multiple times, the staggering varieties of peptides
discovery: biopolymer libraries and small molecules. found in the original library can be narrowed down to a
Biopolymer libraries, which can offer dazzling molecular few peptides with sought-after characteristics.
diversities approaching a trillion or more different com- Li and Roberts use an alternative to phage display in
pounds, are central to this new technology. Libraries of this study. They utilized the mRNA display format that
biopolymers, such as peptides, RNA, or DNA, are readily traces its roots to studies of “polysomes” (multiple ribo-
accessible to researchers and are a standard tool used somes translating an mRNA transcript) carried out in
to generate ligands for a particular target or to screen the 1970s. This technology was improved in a number
for a lead compound or polypeptide drug with improved of ways in the 1990s, including the optimization of mRNA
affinity. The tremendous diversity of such libraries can 5 and 3 end sequences and the addition of chaperones
often provide a starting point for such screens with rela- to the in vitro translation mixture, to facilitate the synthe-
tively little synthetic effort [2]. On the other hand, combi- sis of peptide libraries with diversities greater than 1012
natorial libraries of small molecules are much more labo- different peptides [3, 4]. Perhaps the most significant
rious to prepare and rarely approach the levels of advance in the context of library synthesis was made
diversity possible with biopolymers. However, one cru- by Roberts and Szostak, who developed a technique to
cial advantage of using small molecules is the ability to covalently connect an mRNA to its peptide translation
explore the physical and chemical parameters of com- product [5]. To this end, the antibiotic puromycin and a
plementary molecular diversity well beyond the 20 natu- short DNA linker are first appended to the 3 end of
rally occurring amino acids or 5 nucleotides. Until now, synthetic mRNAs. When the ribosome translates this
combinatorial small molecule and biopolymer libraries modified mRNA, it stalls upon reaching the DNA linker,
and the puromycin at the tail of the mRNA/DNA hybridhave been considered separate approaches to generate
